When did semaglutide go off patent?

Reported as 4 January 2026 in Canada — the first G7 nation — and March 2026 in India, Brazil and China.

Why did generics appear so quickly?

Semaglutide is 31 amino acids, below the 40-residue threshold, so it is regulated as a drug and generics file for bioequivalence rather than as biosimilars.

Does off-patent mean available without prescription?

No. Patent expiry changes who may manufacture it, not its regulatory status or the requirement for a prescription.

Research & Regulatory News

Canada in January, India in March

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Semaglutide patent protection expired in Canada on 4 January 2026 and in India, Brazil and China in March 2026. Reporting indicates multiple manufacturers launched generics in India within days, several at 70 to 90 per cent below the innovator price.

Key facts

Canada: Expired 4 January 2026 — first G7 nation
India, Brazil, China: March 2026
Canadian filers reported: Sandoz, Apotex, Teva, Aspen
India, reported discounts: 70–90% below innovator
India brand count: 40+ reported by end of April
Wave 1 markets: Eight, including Mexico and Turkey
UK and US: Not in this wave

Why patents expire at different times in different countries

Patents are national. A molecule protected in one jurisdiction may be unprotected in another, depending on when and where applications were filed, what term extensions were granted, and whether secondary patents on formulation or use were upheld. A single compound therefore goes off patent in a staggered sequence rather than everywhere at once.

What happened in Canada

Reporting indicates the main protection lapsed on 4 January 2026, making Canada the first G7 country where this occurred, with filings from several established generic manufacturers following. Canada is a substantial market and the first major-economy test of what generic entry does to this class.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What happened in India

Expiry is reported as 20 March 2026, followed within days by launches from several domestic manufacturers, with brand counts reported above 40 by the end of April and prices reported at 70 to 90 per cent below the innovator. India has substantial domestic generic manufacturing capacity, which is why entry there is fast and crowded rather than gradual.

Why the entry is so rapid

Because semaglutide is regulated as a drug rather than a biologic. At 31 amino acids it sits below the 40-residue threshold, so a generic files an abbreviated application demonstrating bioequivalence rather than running the comparative clinical programme a biosimilar requires. That difference is measured in years and in orders of magnitude of cost.

What this does not change

That semaglutide is a prescription medicine. Patent expiry alters who may lawfully manufacture and sell it; it does not alter its regulatory status, the requirement for a prescription, or the standards a product must meet. Off-patent is not the same as unrestricted, and it is the word most likely to be misread that way.

The UK position

The United Kingdom is not in this first wave. UK protection and availability follow their own timeline, and separately from any patent question, NHS funding is determined by NICE rather than by whether a generic exists.

And what it has to do with research material

Nothing. A generic semaglutide is a licensed medicine made by a different company. It does not become a research chemical, and nothing supplied on this site is semaglutide, generic or otherwise, or an alternative to it.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

When did semaglutide go off patent?: Reported as 4 January 2026 in Canada — the first G7 nation — and March 2026 in India, Brazil and China.
Why did generics appear so quickly?: Semaglutide is 31 amino acids, below the 40-residue threshold, so it is regulated as a drug and generics file for bioequivalence rather than as biosimilars.
Does off-patent mean available without prescription?: No. Patent expiry changes who may manufacture it, not its regulatory status or the requirement for a prescription.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum